Research on the mechanisms of action of the renin-angiotensin system has provided a wealth of information about its role in both physiology and cardiovascular pathology. Characterization of newer biochemical pathways by which angiotensin peptides act on diverse cellular receptors to exert modulatory functions through paracrine and intracrine mechanisms include the identification of angiotensin converting enzyme 2 (ACE2), the vasodilator and antiproliferative peptide angiotensin-(1-7) [Ang-(1-7)], and the mas-receptor. Upstream within the biochemical cascade leading to the formation of angiotensin peptides, angiotensinogen (Aogen) remains the undisputed large molecular protein from which Ang II and Ang-(1-7) are generated. This application details studies directed to determine whether a newly described propeptide, cleaved from Aogen by a non-renin pathway, may be an alternate substrate for the formation of the biologically active angiotensins. The dodecapeptide angiotensin-(1-12) [Ang-(1-12)], isolated from rat tissues, has been found to generate Ang II and Ang-(1-7) by a non-renin enzyme and be selectively expressed in large quantities in cardiac myocytes of spontaneously hypertensive rats (SHR). The major goal of the proposed studies is to identify the mechanisms regulating the expression and function of Ang-(1-12) in the heart of both normotensive Wistar Kyoto (WKY) and SHR, explore the intracellular and extracellular pathways by which the substrate is cleaved from Aogen, and assess whether Ang-(1-12) is an alternate or obligatory intermediate peptide for the intracellular action of Ang II and Ang-(1-7). These objectives will be achieved by a combination of histochemical, molecular, cellular, and physiological experiments using both in vivo and in vitro approaches. The research plan includes four Specific Aims.
Specific Aim will determine the expression of Ang-(1-12) in the cellular components of the heart tissue of normal WKY and SHR using a combination of quantitative immunohistochemistry (IHC) and confocal microscopy.
Specific Aim 2 will assess the metabolic pathways for Ang-(1-12) formation and processing into Ang I, Ang II, and Ang-(1-7) in the heart of both strains.
In Specific Aim 3 we will evaluate whether Ang-(1-12) is incorporated or synthesized by cardiac myocytes in culture and whether the presence of the alternate substrate activates a signaling pathway mimicking the effects of Ang II.
Specific Aim 4 will evaluate the role of Ang-(1-12) in the regulation of arterial pressure and cardiac function in both WKY and SHR through assessing the effect of graded doses of Ang-(1-12) infusions, measuring endogenous inhibition of Ang-(1-12) through the administration of a polyclonal Ang-(1-12) antibody to sequester the peptide, or determining the effects of chronic inhibition of renin and other Ang I- and Ang ll-forming enzymes on plasma and cardiac tissue levels of Ang-(1-12). These studies will allow identification of alternate pathways for angiotensin peptide formation upstream of angiotensin I (Ang I), discoveries that should have a major impact in understanding the relative efficacy of renin inhibitors in cardiac remodeling and the development of newer agents that would block the enzyme(s) by which Ang-(1-12) is processed to the active angiotensin peptides.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051952-19
Application #
8378038
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
19
Fiscal Year
2012
Total Cost
$374,142
Indirect Cost
$121,343
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Wang, Hao; Sun, Xuming; Chou, Jeff et al. (2017) Inflammatory and mitochondrial gene expression data in GPER-deficient cardiomyocytes from male and female mice. Data Brief 10:465-473
Ferrario, Carlos M; Mullick, Adam E (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125:57-71
Chappell, Mark C; Al Zayadneh, Ebaa M (2017) Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways. J Cell Signal 2:
Brosnihan, K Bridget; Chappell, Mark C (2017) Measurement of Angiotensin Peptides: HPLC-RIA. Methods Mol Biol 1527:81-99
Wang, Hao; Sun, Xuming; Chou, Jeff et al. (2017) Cardiomyocyte-specific deletion of the G protein-coupled estrogen receptor (GPER) leads to left ventricular dysfunction and adverse remodeling: A sex-specific gene profiling analysis. Biochim Biophys Acta 1863:1870-1882
Butts, Brittany; Goeddel, Lee A; George, David J et al. (2017) Increased Inflammation in Pericardial Fluid Persists 48 Hours After Cardiac Surgery. Circulation 136:2284-2286
Alencar, Allan K; da Silva, Jaqueline S; Lin, Marina et al. (2017) Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344√óBrown Norway Female Rat. J Gerontol A Biol Sci Med Sci 72:152-162
Ahmad, Sarfaraz; Varagic, Jasmina; VonCannon, Jessica L et al. (2016) Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun 478:559-64
Fu, Lianwu; Wei, Chih-Chang; Powell, Pamela C et al. (2016) Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol 92:1-9
Thapa, Narendra; Tan, Xiaojun; Choi, Suyong et al. (2016) The Hidden Conundrum of Phosphoinositide Signaling in Cancer. Trends Cancer 2:378-390

Showing the most recent 10 out of 296 publications